Substance / Medication

Sunitinib malate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Wang Dongchun, Jiang Zhenzhou, Zhang Luyong · Med Oncol · 2012
PMID: 21455800Observational
Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen Timo, Martikainen Janne A, Soini Erkki J O et al. · Clin Ther · 2008
PMID: 18343276Observational
Preoperative therapy with sunitinib malate in a patient with a gastrointestinal stromal tumor and liver metastases: A case report.
Wang Zhi-Qiang, Wen Zheng-Qi, Yang Jun et al. · Medicine (Baltimore) · 2019
PMID: 31860943Case ReportFull text (PMC)
Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma.
Li Xiaoyan, Gao Hongjun, Tang Chuanhao et al. · Onco Targets Ther · 2016
PMID: 27536137Case ReportFull text (PMC)
Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Saada Esma, Saint Paul Marie-Christine, Gugenheim Jean et al. · Oncol Res Treat · 2014
PMID: 24685916Case Report
Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.
Chen Jianpeng, Wang Caixia, Han Junqing et al. · Expert Rev Anticancer Ther · 2013
PMID: 23573816Case Report
Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
Lin Li-Zhu, Li Peng, Chen Han-Rui et al. · Future Oncol · 2013
PMID: 23718311Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sunitinib malate (substance)
SNOMED CT
426455008
UMLS CUI
C1700685

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.